Seabed Selects Velodyne Lidar Sensors for Mobile Mapping System

 

Agendia’s MammaPrint® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

 

Agendia’s MammaPrint® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

 

Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

 

Statement by Next Alt

 

Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

 

Wolters Kluwer Compliance Solutions Earns Four American Business Awards

 

ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes

 

AM Best Revises Issuer Credit Rating Outlook to Stable for Protector Forsikring ASA

 

Innovative PolyStyreneLoop Plant Will Recycle Polystyrene Foam Demolition Waste and Recover Valuable Resources